Skip to main content
Figure 4 | Journal of Translational Medicine

Figure 4

From: Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety

Figure 4

Blood pressure decreased during infusion of rh-HGF in patients with FH or LOHF. BP and HR were monitored during rh-HGF infusion for three hours. Intravenous rh-HGF (0.6 mg/m2) reduced systolic BP, and increased HR in patients 1, 2 and 3. BP reduction during rh-HGF infusion did not affected patients' general condition. BP immediately recovered following the completion of rh-HGF administration.

Back to article page